Ashoka Buildcon DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.82×0.82×1.12×0.59×0.64×
2.18×1.82×0.59×0.47×0.36×
19.4%22.9%26.2%19.2%20.1%
0.44×0.44×0.50×0.54×0.50×
1.98×1.98×4.99×7.89×8.68×
30.3%29.9%43.1%22.7%20.0%
48.6%48.6%55.2%25.3%23.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ASHOKA₹98.97

Ashoka Buildcon Ltd.

· Infrastructure
₹ CrorePeersPNCINFRAKNRCONIRBAHLUCONTDBLHCCHGINFRAPOWERMECHMcap ₹2,778 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.640.591.120.820.82
Interest Burden (Pretax/EBIT) ×0.360.470.591.822.18
EBIT Margin %20.0919.2426.2122.9019.39
Asset Turnover ×0.500.540.500.440.44
Financial Leverage (Assets/Equity) ×8.687.894.991.981.98
ROE (5-step product, year-end total equity) %19.9822.6643.1329.9130.31
ROE (owners' profit / average owners' equity) %23.6925.3155.2248.6048.60
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.